Cagrilintide/semaglutide
REDEFINE 1
Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 3400
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- Cagrisema: week 68 -20.4%
- Placebo s.c.: week 68 -3%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.